

TUMOR NECROSIS FACTOR LEVEL IN PREGNANCY INDUCED HYPERTENSION

Thesis

Submitted for Partial Fulfillment of MD. Degree in
Obstetrics and Gynecology

By

Amr Fathy Ahmad Abdel-Kareem

M.B., B.Ch., M.Sc.

Assistant Lecturer of Obstetrics and Gynecology
Faculty of Medicine - Ain Shams University

Under Supervision of

Prof. Dr. Mohammad Abd-Allah El-Maraghy

Professor of Obstetrics and Gynecology
Faculty of Medicine - Ain Shams University

Prof. Dr. Aly Khalifa Aly

Professor of Biochemistry and
Head of Oncology Diagnostic Unit
Faculty of Medicine - Ain Shams University

Prof. Dr. Khaled El-Maamoun El-Hodaiby

Professor of Obstetrics and Gynecology
Faculty of Medicine - Ain Shams University

Dr. Essam Ahmad Mady

Lecturer of Biochemistry
Faculty of Science - Ain Shams University

Faculty of Medicine
Ain Shams University
1995



بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ
فَالْوِاسْجَانُكَ
وَالْعَالَمِينَ
أَنْتَ الْعَالَمِينَ

(سورة البقرة - آية ٢٥٠)



TO MY FAMILY

ACKNOWLEDGEMENT

I wish to express my deepest gratitude and appreciation to *Prof. Dr. Mohamad Abd-Allah El-Maraghy*, Professor of Obstetrics and Gynecology, Faculty of Medicine, Ain Shams University, for the help, sincere guidance and support he constantly offered throughout the period of preparation of this thesis.

Special thanks and appreciation for *Prof. Dr. Aly Khalifa Aly*, Professor of Biochemistry and Head of Oncology Diagnostic Unit, Faculty of Medicine, Ain Shams University, who offered his precious time and help in achieving this work.

I would like to express my sincere appreciation to *Prof. Dr. Khaled-El-Maamoun El-Hodaihy* Professor of Obstetrics and Gynecology, Faculty of Medicine, Ain Shams University, for his invaluable assistance and his continuous advice to complete this work in a proper manner.

I am also indebted to *Dr. Essam Ahmad Mady*, Lecturer in Biochemistry, Faculty of Science, Ain Shams University, who so willingly offered all technical laboratory facilities and experience to achieve this work.

Last but not least, I would like to thank every patient accepted to be part of this work. Also I would like to thank every person attending the discussion of this thesis.

LIST OF CONTENTS

	<u>Page</u>
INTRODUCTION	1
AIM OF THE WORK	3
REVIEW OF LITERATURE	4
- Pregnancy induced hypertension	4
* Definitions and classification	4
* Etiology	6
* Immunology	12
* Pathogenesis	41
- Tumor necrosis factor (TNF)	65
* Introduction	65
* History	66
* Biochemistry and Biosynthesis	68
* Mechanism of action	71
* Physiologic effects of TNF	72
* Effect of TNF on different tissues	74
* TNF in gynecology	83
* Use of TNF in cancer therapy	90
* TNF in pregnancy	92
* TNF in labor	96
* TNF in pregnancy induced hypertension	101
PATIENTS AND METHODS	105
RESULTS.....	119
DISCUSSION.....	171
SUMMARY AND CONCLUSION	184
REFERENCES.....	188
ARABIC SUMMARY.	

LIST OF FIGURES

	<u>Page</u>
Fig. (1): Cells of the immune response	16
Fig. (2): The uteroplacental circulation in normotensive pregnancy.....	60
Fig. (3): Immunological maladaptation and the uteroplacental circulation in preeclampsia	61
Fig. (4): Standard curve graph	116
Fig. (5): Comparison of age and gestational age between the patient and control group.....	123
Fig. (6): Comparison of systolic and diastolic blood pressure between the patient and control group	124
Fig. (7): Comparison of hemoglobin between the patient and the control group	134
Fig. (8): Comparison of serum creatinine between the patient and the control group	135
Fig. (9): Comparison of serum TNF- α between the patient and control group	137
Fig. (10): Comparison of placental TNF- α between the patient and the control group	138
Fig. (11): Comparison of serum creatinine between the group of mild preeclampsia and the control group	140
Fig. (12): Comparison of serum TNF- α between the group of mild preeclampsia and the control group	141

Fig. (13):	Comparison of placental TNF- α between the group of mild preeclampsia and the control group	142
Fig. (14):	Comparison of serum creatinine between the group of severe preeclampsia and the control group	144
Fig. (15):	Comparison of serum TNF- α between the group of severe preeclampsia and the control group	145
Fig. (16):	Comparison of placental TNF- α between the group of severe preeclampsia and the control group	146
Fig. (17):	Comparison of Hb between the control group and the patient group as a whole and with its subgroups	148
Fig. (18):	Comparison of serum creatinine between the control group and the patient group as a whole and with its subgroups.....	149
Fig. (19):	Comparison of serum TNF α between the control group and the patient group as a whole and with its subgroups.....	150
Fig. (20):	Comparison of placental TNF α between the control group and the patient group as a whole and with its subgroups.....	151
Fig. (21):	Correlation between the age and placental TNF in patient and control group	156
Fig. (22):	Correlation between the age and serum TNF in both groups.....	157
Fig. (23):	Correlation between the gestational age and systolic blood pressure in both groups	158

Fig. (24):	Correlation between the gestational age and diastolic blood pressure in both groups	160
Fig. (25):	Correlation between the gestational age and serum creatinine in both groups	161
Fig. (26):	Correlation between the gestational age and placental TNF- α in both groups	162
Fig. (27):	Correlation between the gestational age and serum TNF- α in both groups	164
Fig. (28):	Correlation between the systolic blood pressure and placental TNF- α in both groups	165
Fig. (29):	Correlation between the systolic blood pressure and serum creatinine in both groups	166
Fig. (30):	Correlation between the diastolic blood pressure and serum creatinine in both groups	168
Fig. (31):	Correlation between serum creatinine and serum TNF in both groups	169
Fig. (32):	Correlation between serum creatinine and hemoglobin in both groups	170

LIST OF TABLES

	<u>Page</u>
Table (1): Mechanisms that may be involved in the non rejection of the allogeneic fetal placental unit	24
Table (2): Observations consistent and non consistent with an immunological explanation of preeclampsia	38
Table (3): Clinical data of the patient group	120
Table (4): Clinical data of the control group	121
Table (5): Comparison of the clinical data between the patient and control group	125
Table (6): Blood group, Hb, serum creatinine, serum TNF α and placental TNF α in the patient group	127
Table (7): Blood group, Hb, serum creatinine, serum TNF α and placental TNF α in the control group	129
Table (8): Blood group, Hb, serum creatinine, serum TNF α and placental TNF α in the group of mild preeclampsia	131
Table (9): Blood group, Hb, serum creatinine, serum TNF α and placental TNF α in the group of severe preeclampsia	132
Table (10): Comparison of hemoglobin and creatinine level between the patient and the control groups	133
Table (11): Comparison of TNF- α values between the patient and the control groups	136

Table (12):	Comparison between the group of mild preeclampsia and the control group regarding Hb, serum creatinine, serum TNF α and placental TNF α ..	139
Table (13):	Comparison between the group of severe pre-eclampsia and the control group regarding Hb, serum creatinine, serum TNF α and placental TNF α ..	143
Table (14):	Comparison of serum TNF α values in both groups regarding the mode of delivery	153
Table (15):	Comparison of placental TNF α values in both groups regarding the mode of delivery	154

LIST OF ABBREVIATIONS

ADP:	Adenosine diphosphate.
AFP:	Alpha feto protein.
AMP:	Adenosine monophosphate.
ATP:	Adenosine triphosphate.
C.S:	Cesarean section.
DNA:	Deoxyribonucleic acid.
EDRF:	Endothelium derived relaxing factor.
EDTA:	Ethylene diamine tetracetic acid.
EPF:	Early pregnancy factor.
gm:	gram.
GM-CSF:	Granulocyte, macrophage-colony stimulating factor.
hCG:	Human chorionic gonadotrophin.
HELLP syndrome:	Syndrome of hemolysis, elevated liver enzymes and low platelet count.
HLA:	Human leucocyte antigen.
hPL:	Human placental lactogen.
IFN γ :	Gamma interferon.
Ig:	Immunoglobulin.
IL:	Interleukin.
IRMA:	Immuno radiometric assay.
ISF:	Immune suppressive factor.
KD:	Kilo dalton.
LPS:	Lipopolysaccharide.
MHC:	Major histocompatibility complex.

ml:	millilitre 1×10^{-3} of the liter
MLC:	Mixed lymphocyte culture.
mRNA:	Messenger ribonucleic acid.
ND:	Normal delivery.
NO:	Nitric oxide.
PAI:	Plasminogen activator inhibitor.
PCR:	Polymerase chain reaction.
PG:	Prostaglandin.
Pg:	Picogram (1×10^{-9} of a gram).
PGI ₂ :	Prostacyclin.
SD:	Standard deviation.
TLX:	Trophoblast lymphocyte cross reactive antigens.
TNF:	Tumor necrosis factor.
tPA:	Tissue type plasminogen activator.
TXA ₂ :	Thromboxane A ₂ .
ul:	Microlitre (1×10^{-6} of a litre).
uPA:	Urokinase type plasminogen activator.

INTRODUCTION

AIM OF THE WORK

INTRODUCTION

Preeclampsia-eclampsia remains one of the most commonly encountered pregnancy induced disorders in Egypt. It is a multifaceted syndrome with variable involvement of several organ system. The classic triad of hypertension, edema, and proteinuria is still the most common presentation (**Chesley, 1985**).

Pre-eclampsia is still the disease of theories. However, it is widely accepted that increased blood pressure is due to either increased sensitivity of the blood vessel wall to the constrictor action of adrenergic amines, angiotensin, and vasopressin, or decreased sensitivity to endogenous vasodilators such as prostacyclin (**Worley, 1984**).

Pre-eclampsia is associated with vascular endothelial cell injury. This injury leads to disturbed prostacyclin/thromboxane ratio with dominance of thromboxane (a potent vasoconstrictor), as the injured endothelium cannot produce prostacyclin. This endothelial injury can also explain the activity of coagulation cascade and the associated cardiovascular complications occurring in the disease (**Roberts et al., 1989**).